Investigational Blood Test Identifies Patients with Melanoma Who Are More Likely to Have Improved Survival on Nivolumab Therapy; Biodesix’ blood test is independent of PD-L1 expression
Investigational blood test identifies patients with melanoma who are more likely to have improved survival on Nivolumab therapy.